Conventional Longer MDR-TB Regimen (Injectable-containing)
Treatment for Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Typical Dosage: Highly variable, individualized; includes an injectable drug for 6-8 months, and at least 4-5 second-line oral drugs
Effectiveness
60%
Safety Score
40%
Clinical Trials
100
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
Highly variable, individualized; includes an injectable drug for 6-8 months, and at least 4-5 second-line oral drugs
Time to Effect
3-4 months for culture conversion
Treatment Duration
18-24 months
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$4,000
Monitoring:$6,000
Side Effect Mgmt:$5,000
Total Annual:$15,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$150,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$24,194
Cost per Remission
$25,862
Conventional Longer MDR-TB Regimen (Injectable-containing) Outcomes
for Multidrug Resistant Tuberculosis Without Extensive Drug Resistance
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+62%
Remission Rate
+58%
Common Side Effects
Hearing loss/vestibular toxicity (injectables)
+40%
Nephrotoxicity (injectables)
+25%
Gastrointestinal intolerance
+60%
Psychiatric disturbances (Cycloserine)
+15%
Hypothyroidism (Ethionamide, PAS)
+15%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov